Meeting
2023 ASCO Genitourinary Cancers Symposium
Neoadjuvant pembrolizumab for cisplatin-ineligible muscle-invasive bladder cancer prior to radical cystectomy.
Authors
Kyle M Rose
H. Lee Moffitt Cancer Center, Tampa, FL
Kyle M Rose , Marco Bandini , Heather L Huelster , Giuseppe Basile , Shreyas U Naidu , Philippe E. Spiess , Andrea Necchi , Roger Li
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer and Urothelial Carcinoma
Track
Urothelial Carcinoma,Prostate Cancer - Advanced
Sub Track
Therapeutics
Citation
J Clin Oncol 41, 2023 (suppl 6; abstr 513)
DOI
10.1200/JCO.2023.41.6_suppl.513
Abstract #
513
Poster Bd #
K17
Abstract Disclosures
Similar Posters
Poster
2020 Genitourinary Cancers Symposium
Durvalumab as neoadjuvant therapy for muscle-invasive bladder cancer: Preliminary results from the Bladder Cancer Signal Seeking Trial (BLASST)-2.
First Author: Xiao X. Wei
Poster
2024 ASCO Genitourinary Cancers Symposium
Comprehensive genomic profiling (CGP) of clinical T2-4N0M0 muscle-invasive bladder cancer (MIBC) treated with neoadjuvant pembrolizumab or cisplatin-based chemotherapy before radical cystectomy (RC).
First Author: Chiara Mercinelli
Poster
2024 ASCO Genitourinary Cancers Symposium
First results of NURE-Combo: A phase 2 study of neoadjuvant nivolumab (NIVO) and nab-paclitaxel (ABX) followed by postsurgical adjuvant NIVO in patients (pts) with muscle-invasive bladder cancer (MIBC).
First Author: Chiara Mercinelli
Poster
2024 ASCO Genitourinary Cancers Symposium
Phase 3 KEYNOTE-992 study of pembrolizumab plus chemoradiotherapy versus placebo plus chemoradiotherapy in patients with muscle-invasive bladder cancer (MIBC).
First Author: Shilpa Gupta